Aminoquinazolines as TRPV1 antagonists: Modulation of drug-like properties through the exploration of 2-position substitution

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 16, 2008, Pages 4573-4577

  Blum, Charles A ^a   Zheng, Xiaozhang ^a   Brielmann, Harry ^a   Hodgetts, Kevin J ^a   Bakthavatchalam, Rajagopal ^a   Chandrasekhar, Jayaraman ^a   Krause, James E ^a   Cortright, Daniel ^a   Matson, David ^a   Crandall, Marci ^a   Ngo, Chu K ^a   Fung, Lawrence ^a   Day, Marta ^a   Kershaw, Mark ^a   De Lombaert, Stéphane ^a   Chenard, Bertrand L ^a  

^a NEUROGEN CORPORATION   (United States)

Author keywords

Aminoquinazolines; Antagonists; TRPV1; VR1

Indexed keywords

QUINAZOLINE DERIVATIVE; VANILLOID RECEPTOR 1;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HUMAN; IN VIVO STUDY; MODULATION; NONHUMAN; PAIN; RAT; STRUCTURE ACTIVITY RELATION;

AMINOQUINOLINES; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DOGS; DRUG DESIGN; ETHER-A-GO-GO POTASSIUM CHANNELS; INFLAMMATION; KINETICS; MODELS, CHEMICAL; MOLECULAR CONFORMATION; PAIN; PHARMACEUTICAL PREPARATIONS; RATS; TRPV CATION CHANNELS;

RATTUS;

EID: 48649096712     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.07.036     Document Type: Article

References (25)

1. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., and Julius D. Nature 389 (1997) 816
2. Szallasi A., Cortright D.N., Blum C.A., and Eid S.R. Nat. Rev. Drug Disc. 6 (2007) 357
3. For recent reviews see:. Szallasi A., and Appendino G. J. Med. Chem. 47 (2004) 2717
4. Roberts L.A., and Connor M. Recent Patents on CNS Drug Discovery 1 (2006) 65
5. Rami H.K., and Gunthorpe M.J. Drug Discovery Today: Therapeutic Strategies 1 (2004) 97
6. For leading examples of TRPV1 antagonists see:. Rami H.R., Thompson M., Stemp G., Fell S., Jerman J.C., Stevens A.J., Smart D., Sargent B., Sanderson D., Randall A.D., Gunthorpe M.J., and Davis J.B. Bioorg. Med. Chem. Lett. 16 (2006) 3287
7. Wang H.-L., Katon J., Balan C., Bannon A.W., Bernard C., Doherty E.M., Dominguez C., Gavva N.R., Gore V., Ma V., Nishimura N., Surapaneni S., Tang P., Tamir R., Thiel O., Treanor J.J.S., and Norman M.H. J. Med. Chem. 50 (2007) 3528
8. Ognyanov V.I., Chenera Balan C., Bannon A.W., Bo Y., Dominguez C., Fotsch C., Gore V.K., Klionsky L., Ma V.V., Qian Y.-X., Tamir R., Wang X., Xi N., Xu S., Zhu D., Gavva N.R., Treanor J.J.S., and Norman M.H. J. Med. Chem. 49 (2006) 3719
9. Gomtsyan A., Bayburt E.K., Keddy R., Turner S.C., Jinkerson T.K., Didomenico S., Perner R.J., Koenig J.R., Drizin I., McDonald H.A., Surowy C.S., Honore P., Mikusa J., Marsh K.C., Wetter J.M., Faltynek C.R., and Lee C.-H. Bioorg. Med. Chem. Lett. 17 (2007) 3894
10. Shishido Y., Jinno M., Ikeda T., Ito F., Sudo M., Makita N., Ohta A., Iki-Taki A., Ohmi T., Kanai Y., Tamura T., and Shimojo M. Bioorg. Med. Chem. Lett. 18 (2008) 1072
11. Chizh B., O'Donnell M., Napolitano A., Wang J., Brooke A., Aylott M., Bullman J., Gray E., Lai R., and Williams P. Pain 132 (2007) 132
12. Gavva N.R., Treanor J.J.S., Garami A., Fang L., Surapaneni S., Akrami A., Alvarez F., Bak A., Darling M., Gore A., Jang G.R., Kesslak J.P., Ni L., Norman M.H., Palluconi G., Rose M.J., Salfi M., Tan E., Romanovsky A.A., Banfield C., and Davar G. J. Endodontics 136 (2008) 202
13. Zheng X., Hodgetts K., Brielmann H., Hutchison A., Burkamp F., Jones A.B., Blurton P., Clarkson R., Chandrasekhar J., Bakthavatchalam R., De Lombaert S., Crandall M., Cortright D., and Blum C.A. Bioorg. Med. Chem. Lett. 16 (2006) 5217
14. Zheng, X.; Blum, C. A.; Hodgetts, K. J.; Brielmann, H.; Hutchison, A.; Chenard, B. L.; Burkamp, F.; Jones, A. B.; Blurton, P.; Clarkson, R.; Chandrasekhar, J.; Bakthavatchalam, R.; De Lombaert, S.; Crandall, M.; Matson, D.; Cortright, D. From arylureas to biarylamides to aminoquinazolines: discovery of a novel, potent TRPV1 (VR1) antagonist. The 232nd National Meeting of the American Chemical Society, San Francisco, CA, September 12-14, 2006; MEDI 315.
15. DeSimone, R. W.; Hodgetts, K.; Krause, J. E.; White, G. PCT WO 02/08221.
16. Bakthavatchalam, R.; Hutchison, A.; DeSimone, R. W.; Hodgetts, K.; Krause, J. E.; White, G. U.S. Patent 6,723,730, 2004.
17. Vitamin E TPGS is d-alpha-tocopheryl polyethylene glycol 1000 succinate.
18. Aqueous solubility was assessed using a high-throughput format assay (HTSol) by diluting DMSO stock solutions of the test article into pH 7.4 buffer and shaking for 4 h at room temperature. Solutions were then filtered and analyzed (HPLC/MS).
19. There is ample precedent for successfully using phosphate pro-drugs for the parenteral delivery of poorly water-soluble drugs. Preliminary in vitro experiments in our laboratory suggested that in fact the phosphate group on 22 could be readily cleaved in the presence of alkaline phosphatase. Phosphatase cleavage experiments: 550 μmol of substrate 22, 20 μL of calf intestine alkaline phosphatase (equiv to 20 U), and 150 μL of buffer (pH 7.6), at 40 °C for 2 h. Disappearance of 22 and appearance of 17 were monitored by HPLC.
20. Octanol-water partition coefficients (c log P) were calculated using the BioByte ClogP 4.0 estimator, as implemented in the Daylight Chemical Information System software, v. 4.71. Daylight Chemical Information Systems, Mission Viejo, CA.
21. a values were determined potentiometrically.
22. Swanson D.M., Dubin A.E., Shah C., Nasser N., Chang L., Dax S.L., Jetter M., Breitenbucher J.G., Liu C., Mazur C., Lord B., Gonzales L., Hoey K., Rizzolio M., Bogenstaetter M., Codd E.E., Lee D.H., Zhang S.P., Chaplan S.R., and Carruthers N.I. J. Med. Chem. 48 (2005) 1857
23. Compounds were incubated with pooled human or rat liver microsomes. The rates of oxidative metabolism were measured under the following conditions: compound, 1 μM final concentration; final microsomal protein concentration approximately 1 mg/mL; NADPH, 0.5 mM; pH 7.4 sodium phosphate buffer. Incubations were performed at 39 °C and were initiated by the addition of NADPH. Samples (50 μL) were taken from each incubation well at about 0.25, 1, 5, 10, and 30 min and added to 75 μL of ice-cold acetonitrile. The aliquot mixtures were mixed and then centrifuged at 3000 rpm for 15 min. The supernatant was analyzed for parent compound using LC/MS and the percent metabolized was calculated based on disappearance of parent compound.
24. Sprague-Dawley rats (n = 11-12/group) were administered vehicle, Ibuprofen, or 18 via oral gavage (2% vitamin E-TPGS vehicle) 4 h pre-test. Carrageenan (1%) was injected subcutaneously into the plantar surface of the paw 3 h pre-test. Results are expressed as % of maximum potential effect (MPE, y-axis) wherein 0% MPE is equivalent to a vehicle treatment group response and 100% MPE is equivalent to complete reversal of thermal hyperalgesia. Statistical analysis was performed by one way analysis of variance with post hoc analysis using Fisher's least significant difference test. Statistical significance was accepted as P < 0.05.
25. Cui M., Honore P., Zhong C., Gauvin D., Mikusa J., Hernandez G., Chandran P., Gomtsyan A., Brown B., Bayburt E.K., Marsh K., Bianchi B., McDonald H., Niforatos W., Neelands T.R., Moreland R.B., Decker M.W., Lee C.-H., Sullivan J.P., and Faltynek C.R. J. Neurosci. 26 (2006) 9385